Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ101MR)

This product GTTS-WQ101MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ101MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1037MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ2916MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ1976MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ13558MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ11404MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ636MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ12950MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ11873MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW